Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis

Critical Care

Volumn 15, Issue 2, 2011, Pages

  Lorente, Leonardo ^a   Martín, María M ^b   Varo, Nerea ^c   Borreguero León, Juan María ^a   Solé Violán, Jordi ^d   Blanquer, José ^e   Labarta, Lorenzo ^f   Díaz, César ^g   Jiménez, Alejandro ^a   Pastor, Eduardo ^a   Belmonte, Felipe ^b   Orbe, Josune ^h   Rodríguez, José A ^h   Gómez Melini, Eduardo ^a   Ferrer Agüero, José M ^d   Ferreres, José ^e   LLimiñana, María C ^f   Páramo, José A ^h  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^f HOSPITAL SAN JORGE   (Spain)

^g HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^h UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD40 LIGAND; INTERLEUKIN 10; SOLUBLE CD40 LIGAND; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPSIS; SURVIVAL; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; SURVIVAL RATE;

AGED; BIOLOGICAL MARKERS; CD40 LIGAND; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEPSIS; SURVIVAL RATE;

EID: 79952572090     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10104     Document Type: Article

References (49)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310. 10.1097/00003246-200107000-00002, 11445675.
2. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 2009, 54:669-677. 10.1016/j.jacc.2009.03.076, 19679244.
3. Ferroni P, Santilli F, Guadagni F, Basili S, Davì G. Contribution of platelet-derived CD40 ligand to inflammation, thrombosis and neoangiogenesis. Curr Med Chem 2007, 14:2170-2180. 10.2174/092986707781389664, 17691955.
4. Aukrust P, Damås JK, Solum NO. Soluble CD40 ligand and platelets: self-perpetuating pathogenic loop in thrombosis and inflammation?. J Am Coll Cardiol 2004, 43:2326-2328. 10.1016/j.jacc.2004.03.023, 15193701.
5. Anand SX, Viles-Gonzalez JF, Badimon JJ, Cavusoglu E, Marmur JD. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 2003, 90:377-384.
6. Mach F, Schönbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, Libby P. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997, 94:1931-1936. 10.1073/pnas.94.5.1931, 20020, 9050882.
7. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci U S A 1992, 89:6550-6554. 10.1073/pnas.89.14.6550, 1378631.
8. Zhou L, Stordeur P, de Lavareille A, Thielemans K, Capel P, Goldman M, Pradier O. CD40 engagement on endothelial cells promotes tissue factor-dependent procoagulant activity. Thromb Haemost 1998, 79:1025-1028.
9. Hezi-Yamit A, Wong PW, Bien-Ly N, Komuves LG, Prasad KS, Phillips DR, Sinha U. Synergistic induction of tissue factor by coagulation factor Xa and TNF: evidence for involvement of negative regulatory signaling cascades. Proc Natl Acad Sci USA 2005, 102:12077-12082. 10.1073/pnas.0504526102, 1189324, 16105945.
10. Miller DL, Yaron R, Yellin MJ. CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression. J Leukoc Biol 1998, 63:373-379.
11. Slupsky JR, Kalbas M, Willuweit A, Henn V, Kroczek RA, Müller-Berghaus G. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost 1998, 80:1008-1014.
12. Prasad KS, Andre P, He M, Bao M, Manganello J, Phillips DR. Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci USA 2003, 100:12367-12371. 10.1073/pnas.2032886100, 218764, 14519852.
13. André P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, Wagner DD. CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism. Nat Med 2002, 8:247-252.
14. Aukrust P, Muller F, Ueland T, Berget T, Aaser E, Brunsvig A, Solum NO, Forfang K, Frøland SS, Gullestad L. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999, 100:614-620.
15. Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, Gibson CM, Cannon CP, Braunwald E, Schonbeck U. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 2003, 108:1049-1052. 10.1161/01.CIR.0000088521.04017.13, 12912804.
16. Garlichs CD, Kozina S, Fateh-Moghadam S, Tomandl B, Stumpf C, Eskafi S, Raaz D, Schmeier A, Yilmaz A, Ludwig J, Neundörfer B, Daniel WG. Upregulation of CD40-CD40 Ligand (CD154) in patients with acute cerebral ischemia. Stroke 2003, 34:1412-1418. 10.1161/01.STR.0000074032.64049.47, 12764232.
17. Vakkalanka RK, Woo C, Kirou KA, Koshy M, Berger D, Crow MK. Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum 1999, 42:871-881. 10.1002/1529-0131(199905)42:5<871::AID-ANR5>3.0.CO;2-J, 10323442.
18. Clodi K, Asgary Z, Zhao S, Kliche KO, Cabanillas F, Andreeff M, Younes A. Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. Br J Haematol 1998, 103:270-275. 10.1046/j.1365-2141.1998.01031.x, 9792321.
19. Ding Y, Chung CS, Newton S, Chen Y, Carlton S, Albina JE, Ayala A. Polymicrobial sepsis induces divergent effects on splenic and peritoneal dendritic cell function in mice. Shock 2004, 22:137-144. 10.1097/01.shk.0000131194.80038.3f, 2253681, 15257086.
20. Rahman M, Zhang S, Chew M, Ersson A, Jeppsson B, Thorlacius H. Platelet-derived CD40L (CD154) mediates neutrophil upregulation of Mac-1 and recruitment in septic lung injury. Ann Surg 2009, 250:783-790. 10.1097/SLA.0b013e3181bd95b7, 19806052.
21. Inwald DP, Faust SN, Lister P, Peters MJ, Levin M, Heyderman R, Klein NJ. Platelet and soluble CD40L in meningococcal sepsis. Intensive Care Med 2006, 32:1432-1437. 10.1007/s00134-006-0250-2, 16810523.
22. Damås JK, Jensenius M, Ueland T, Otterdal K, Yndestad A, Frøland SS, Rolain JM, Myrvang B, Raoult D, Aukrust P. Increased levels of soluble CD40L in African tick bite fever: possible involvement of TLRs in the pathogenic interaction between Rickettsia africae, endothelial cells, and platelets. J Immunol 2006, 177:2699-2706.
23. Mizusawa M, Kawamura M, Takamori M, Kashiyama T, Fujita A, Usuzawa M, Saitoh H, Ashino Y, Yano I, Hattori T. Increased synthesis of anti-tuberculous glycolipid immunoglobulin G (IgG) and IgA with cavity formation in patients with pulmonary tuberculosis. Clin Vaccine Immunol 2008, 15:544-548. 10.1128/CVI.00355-07, 2268253, 18184828.
24. Chegou NN, Black GF, Kidd M, van Helden PD, Walzl G. Host markers in QuantiFERON supernatants differentiate active TB from latent TB infection: preliminary report. BMC Pulm Med 2009, 9:21. 10.1186/1471-2466-9-21, 2696407, 19445695.
25. Nolan A, Weiden M, Kelly A, Hoshino Y, Hoshino S, Mehta N, Gold JA. CD40 and CD80/86 act synergistically to regulate inflammation and mortality in polymicrobial sepsis. Am J Respir Crit Care Med 2008, 177:301-308. 10.1164/rccm.200703-515OC, 2218847, 17989345.
26. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, . International Sepsis Definitions Conference 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003, 29:530-538. International Sepsis Definitions Conference.
27. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II. a severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
28. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG, . for the Working Group on Sepsis-related Problems of the European Society of Intensive Care Medicine The Sepsis-related Organ Failure Assessment (SOFA) score to describe organ dysfunction/failure. Intensive Care Med 1996, 22:707-710. 10.1007/BF01709751, 8844239, for the Working Group on Sepsis-related Problems of the European Society of Intensive Care Medicine.
29. Hintze JL. ROC curves. NCSS 6.0 User's Guide-II 1995, 1099-1110. Kaysville, Utah: Number Cruncher Statistical Systems.
30. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845. 10.2307/2531595, 3203132.
31. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Kaski JC. Soluble CD40 ligand:interleukin-10 ratio predicts in-hospital adverse events in patients with ST-segment elevation myocardial infarction. Thromb Res 2007, 121:293-299. 10.1016/j.thromres.2007.04.007, 17521712.
32. Chen Y, Chen J, Xiong Y, Da Q, Xu Y, Jiang X, Tang H. Internalization of CD40 regulates its signal transduction in vascular endothelial cells. Biochem Biophys Res Commun 2006, 345:106-117. 10.1016/j.bbrc.2006.04.034, 16677604.
33. Warkentin TE, Aird WC, Rand JH. Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program 2003, 497-519.
34. Levi M. Platelets at a crossroad of pathogenic pathways in sepsis. J Thromb Haemost 2004, 2:2094-2095. 10.1111/j.1538-7836.2004.01004.x, 15613011.
35. Weber M, Rabenau B, Stanisch M, Elsaesser A, Mitrovic V, Heeschen C, Hamm C. Influence of sample type and storage conditions on soluble CD40 ligand assessment. Clin Chem 2006, 52:888-891. 10.1373/clinchem.2005.062083, 16527885.
36. Cognasse F, Boussoulade F, Chavarin P, Acquart S, Fabrigli P, Lamy B, Garraud O. Release of potential immunomodulatory factors during platelet storage. Transfusion 2006, 46:1184-1189. 10.1111/j.1537-2995.2006.00869.x, 16836566.
37. Khan SY, Kelher MR, Heal JM, Blumberg N, Boshkov LK, Phipps R, Gettings KF, McLaughlin NJ, Silliman CC. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood 2006, 108:2455-2462. 10.1182/blood-2006-04-017251, 1895564, 16772606.
38. Kalady MF, Onaitis MW, Emani S, Abdel-Wahab Z, Tyler DS, Pruitt SK. Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity. J Surg Res 2004, 116:24-31. 10.1016/j.jss.2003.09.003, 14732346.
39. John J, Woodward DB, Wang Y, Yan SB, Fisher D, Kinasewitz GT, Heiselman D. Troponin-I as a prognosticator of mortality in severe sepsis patients. J Crit Care 2010, 25:270-275. 10.1016/j.jcrc.2009.12.001, 20149590.
40. Røsjø H, Varpula M, Hagve TA, Karlsson S, Ruokonen E, Pettilä V, Omland T, . FINNSEPSIS Study Group Circulating high sensitivity troponin T in severe sepsis and septic shock: distribution, associated factors, and relation to outcome. Intensive Care Med 2011, 37:77-85. 3020309, 20938765, FINNSEPSIS Study Group.
41. Mehta NJ, Khan IA, Gupta V, Jani K, Gowda RM, Smith PR. Cardiac troponin I predicts myocardial dysfunction and adverse outcome in septic shock. Int J Cardiol 2004, 95:13-17. 10.1016/j.ijcard.2003.02.005, 15159032.
42. Li J, Zhao SP, Peng DQ, Xu ZM, Zhou HN. Early effect of pravastatin on serum soluble CD40L, matrix metalloproteinase-9, and C-reactive protein in patients with acute myocardial infarction. Clin Chem 2004, 50:1696-1699. 10.1373/clinchem.2003.030940, 15265816.
43. Tleyjeh IM, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, Sutton AJ, Ibrahim T. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009, 169:1658-1667. 10.1001/archinternmed.2009.286, 19822822.
44. Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP, Sørensen HT. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch Intern Med 2008, 168:2081-2087. 10.1001/archinte.168.19.2081, 18955636.
45. Hsu J, Andes DR, Knasinski V, Pirsch J, Safdar N. Statins are associated with improved outcomes of bloodstream infection in solid-organ transplant recipients. Eur J Clin Microbiol Infect Dis 2009, 28:1343-1351. 10.1007/s10096-009-0787-4, 19669657.
46. Dobesh PP, Klepser DG, McGuire TR, Morgan CW, Olsen KM. Reduction in mortality associated with statin therapy in patients with severe sepsis. Pharmacotherapy 2009, 29:621-630. 10.1592/phco.29.6.621, 19476415.
47. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000, 6:114. 10.1038/72162, 10655072.
48. Robles-Carrillo L, Meyer T, Hatfield M, Desai H, Dávila M, Langer F, Amaya M, Garber E, Francis JL, Hsu YM, Amirkhosravi A. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J Immunol 2010, 185:1577-1583. 10.4049/jimmunol.0903888, 20585032.
49. Sidiropoulos PI, Boumpas DT. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004, 13:391-397. 10.1191/0961203304lu1032oa, 15230298.